Delivering precision oncology to patients with cancer

J Mateo, L Steuten, P Aftimos, F André, M Davies… - Nature medicine, 2022 - nature.com
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Five-year outcomes from the randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non–small-cell lung cancer

H Borghaei, S Gettinger, EE Vokes… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Immunotherapy has revolutionized the treatment of advanced non–small-cell
lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057) …

Perioperative ctDNA-based molecular residual disease detection for non–small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1)

L Xia, J Mei, R Kang, S Deng, Y Chen, Y Yang… - Clinical Cancer …, 2022 - AACR
Purpose: We assessed whether perioperative circulating tumor DNA (ctDNA) could be a
biomarker for early detection of molecular residual disease (MRD) and prediction of …

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open …

DA Palma, R Olson, S Harrow, S Gaede, AV Louie… - The Lancet, 2019 - thelancet.com
Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

MD Hellmann, TE Ciuleanu, A Pluzanski… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …

[HTML][HTML] Early lung cancer diagnostic biomarker discovery by machine learning methods

Y Xie, WY Meng, RZ Li, YW Wang, X Qian, C Chan… - Translational …, 2021 - Elsevier
Early diagnosis has been proved to improve survival rate of lung cancer patients. The
availability of blood-based screening could increase early lung cancer patient uptake. Our …

Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling

AA Chaudhuri, JJ Chabon, AF Lovejoy, AM Newman… - Cancer discovery, 2017 - AACR
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could
facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer …

Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors

J Tsurutani, H Iwata, I Krop, PA Jänne, T Doi… - Cancer discovery, 2020 - AACR
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …